The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
Mental health and substance use disorders, including addiction to opioids, are the leading cause of disease burden in the United States, and the U.S. has the highest mortality rate for these disorders among similarly wealthy countries. This slideshow explores the prevalence, outcomes, access to care, and costs of mental health disorders and substance abuse in the United States.
As the White House and Congress continue to debate new funding and other actions to address the nation’s opioid epidemic, the latest Kaiser Health Tracking Poll finds that most Americans believe the federal government is not doing enough to combat the recent increases in the number of people who are addicted to prescription painkillers (66%) or heroin (62%). State governments fare no better in the public’s view, with similarly large shares saying they aren’t doing…
The Kaiser Family Foundation Survey of Pennsylvania Residents measures Pennsylvanians’ opinions about a selection of health issues, including which issues they believe state policymakers should prioritize, opinions about prescription painkiller abuse, and experiences accessing and paying for health care. The survey was conducted March 7-15, 2016 among a representative sample of 804 adults ages 18 and over living in Pennsylvania.
Recent Trends in Prescription Drug Costs_JAMA 040516 Download View JAMA infographic
This Visualizing Health Policy infographic with JAMA spotlights national spending on prescription drugs and the public’s views on pharmaceutical prices.
This Visualizing Health Policy infographic spotlights national spending on prescription drugs and the public’s views on pharmaceutical prices. Prescription drug spending rose sharply in 2014, driven by growth in expenditures on specialty drugs, including medications to treat cancer and hepatitis C. Medicare’s spending on prescription pharmaceuticals also has risen, largely due to the addition of the Medicare prescription drug benefit in 2006: between 2004 and 2014, the program’s share of US drug expenditures increased from…
National health spending started to grow more rapidly recently after several years of unusually slow growth. This analysis from the Kaiser Family Foundation and the federal Bureau of Economic Analysis helps to dissect why that may be happening. Using recently-released disease-based health spending data compiled by the federal government, the analysis finds that the drivers of health spending growth shifted in the years following the Great Recession. The number of people treated for various diseases picked up,…
In response to rising drug costs, some policymakers and presidential candidates, including Republican Donald Trump and Democrats Hillary Clinton and Bernie Sanders, have proposed allowing Medicare to negotiate directly with pharmaceutical companies over the price of prescription drugs, in contrast to the current approach under Medicare Part D drug where private plans do the negotiating. A version of this proposal was also included in the Obama Administration’s FY 2016 and FY 2017 budgets. While the…
In this column for The Wall Street Journal's Think Tank, Drew Altman explores the data behind public concern about prescription drug costs and highlights that the people most in need are the most burdened by the problem.
In his latest column for The Wall Street Journal‘s Think Tank, Drew Altman explains why prescription drug spending may be a larger share of health spending than most people think, depending on how you look at it. All previous columns by Drew Altman are online.
© 2026 KFF